GI
Insider
Gilead Sciences, Inc.
10% ownerGilead Sciences, Inc. (10% owner) filed 1 Form 4 report as a reporting entity in the trailing twelve months (1 purchase, 0 sales, 1 filed past the two-business-day deadline), most often in ASMB. Across 1 priced purchase filing, the average 21-session return was +7.0% from execution and +30.6% from disclosure (delay-adjusted; derived). The median gap between execution and disclosure was 56 days.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
+7.0%
avg across 1 priced filings
Delay-adjustediThe same average, entered at disclosure dates
+30.6%
same 1 filings, from disclosure
Filings, ttm
1
1 buys · 0 sells · 1 late
Median delay
56d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$55.0M
shares × price, as filed
Last traded
Aug 8 2025
Filed Oct 3 2025
Median ADV $38.5M across their filed names
Impact on $10,000 · 12M
$13,063 (+30.6%)
S&P 500 $11,725 (+17.2%) · 13.4 pts ahead
Gilead Sciences, Inc.
S&P 500
Compounded across filings from disclosure dates · past 12 months
Open performance→Volume by month
Buys $92.0M
Sells $0
Shares × price, as filed · by filing month · past 24 months
Most traded names
ASMB
ASMB
ASMB · 2 buys · 0 sells
2 filings
RCUSRecent filings
ASMBPURCHASE
ASSEMBLY BIOSCIENCES, INC.
View filing →
$55.0Mas filed
Exec Aug 8 2025
Filed Oct 3 2025 · 4:30 PM ET † RCUSPURCHASE Arcus Biosciences, Inc. View filing → $15.0M
1,363,636 sh × $11.00
Exec Feb 18 2025
Filed Feb 20 2025 · 5:30 PM ET ASMBPURCHASE ASSEMBLY BIOSCIENCES, INC. View filing → $20.1M
940,499 sh × $21.37
Exec Dec 19 2024
Filed Dec 23 2024 · 5:30 PM ET XLOPURCHASE Xilio Therapeutics, Inc. View filing → $1.8M
1,759,978 sh × $1.04
Exec Dec 18 2024
Filed Dec 19 2024 · 5:30 PM ET